Ibrutinib protects T cells in patients with CLL from proliferation-induced senescence

BACKGROUND: The development of Bruton’s tyrosine kinase inhibitors (BTKi) for the treatment of chronic lymphocytic leukaemia (CLL) has provided a highly effective and relatively non-toxic alternative to conventional chemotherapy. Some studies have shown that BTKi can also lead to improvements in T c...

Descripción completa

Detalles Bibliográficos
Autores principales: Davis, Joanne E., Sharpe, Chia, Mason, Kylie, Tam, Constantine S., Koldej, Rachel M., Ritchie, David S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609739/
https://www.ncbi.nlm.nih.gov/pubmed/34809665
http://dx.doi.org/10.1186/s12967-021-03136-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609739/
https://www.ncbi.nlm.nih.gov/pubmed/34809665
http://dx.doi.org/10.1186/s12967-021-03136-2

Ejemplares similares